Concepts (173)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Barrett Esophagus | 4 | 2012 | 94 | 0.300 |
Why?
|
| Esophageal Neoplasms | 4 | 2012 | 344 | 0.260 |
Why?
|
| Precancerous Conditions | 3 | 2012 | 205 | 0.220 |
Why?
|
| Hydrocortisone | 1 | 2005 | 296 | 0.210 |
Why?
|
| Alcoholism | 1 | 2005 | 188 | 0.210 |
Why?
|
| Stress, Psychological | 1 | 2005 | 342 | 0.190 |
Why?
|
| Prostatectomy | 5 | 2008 | 478 | 0.180 |
Why?
|
| Foot Diseases | 1 | 2021 | 12 | 0.170 |
Why?
|
| Robotics | 4 | 2008 | 269 | 0.170 |
Why?
|
| Ankle | 1 | 2021 | 27 | 0.170 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2021 | 25 | 0.170 |
Why?
|
| Telemedicine | 2 | 2021 | 225 | 0.170 |
Why?
|
| Orthopedics | 1 | 2021 | 134 | 0.150 |
Why?
|
| Diabetes Complications | 1 | 2020 | 170 | 0.150 |
Why?
|
| Hyperglycemia | 1 | 2020 | 181 | 0.150 |
Why?
|
| Esophagoscopy | 2 | 2009 | 91 | 0.140 |
Why?
|
| Laparoscopy | 5 | 2008 | 782 | 0.140 |
Why?
|
| Perioperative Care | 1 | 2020 | 188 | 0.140 |
Why?
|
| Hypoglycemic Agents | 1 | 2020 | 379 | 0.130 |
Why?
|
| Adenocarcinoma | 3 | 2009 | 1173 | 0.130 |
Why?
|
| Erectile Dysfunction | 2 | 2008 | 78 | 0.130 |
Why?
|
| Prostatic Neoplasms | 4 | 2007 | 1775 | 0.120 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 452 | 0.120 |
Why?
|
| Carmustine | 2 | 2005 | 71 | 0.120 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 2 | 2005 | 118 | 0.110 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2020 | 506 | 0.110 |
Why?
|
| Pandemics | 1 | 2021 | 873 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2010 | 2544 | 0.110 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2005 | 134 | 0.110 |
Why?
|
| Guanine | 2 | 2005 | 194 | 0.110 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 754 | 0.100 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 767 | 0.100 |
Why?
|
| Postoperative Complications | 4 | 2020 | 2562 | 0.100 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2010 | 939 | 0.100 |
Why?
|
| Lymphoma | 2 | 2010 | 247 | 0.090 |
Why?
|
| Esophagectomy | 2 | 2009 | 92 | 0.080 |
Why?
|
| Risk Assessment | 5 | 2009 | 2441 | 0.080 |
Why?
|
| Neovascularization, Pathologic | 1 | 2012 | 353 | 0.080 |
Why?
|
| Mediastinal Neoplasms | 1 | 2010 | 43 | 0.080 |
Why?
|
| Treatment Outcome | 10 | 2020 | 9099 | 0.080 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2010 | 61 | 0.080 |
Why?
|
| Myeloid Cells | 1 | 2010 | 119 | 0.080 |
Why?
|
| Transplantation Chimera | 1 | 2009 | 84 | 0.080 |
Why?
|
| Antibodies, Neoplasm | 1 | 2009 | 85 | 0.080 |
Why?
|
| Carcinoma | 1 | 2012 | 439 | 0.070 |
Why?
|
| Abnormalities, Multiple | 1 | 2010 | 237 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2010 | 1914 | 0.070 |
Why?
|
| Neoplasms, Second Primary | 1 | 2010 | 245 | 0.070 |
Why?
|
| Sural Nerve | 1 | 2007 | 17 | 0.070 |
Why?
|
| Urination Disorders | 1 | 2008 | 55 | 0.070 |
Why?
|
| Transplantation Conditioning | 1 | 2009 | 383 | 0.070 |
Why?
|
| Quinazolines | 1 | 2008 | 211 | 0.060 |
Why?
|
| Aged, 80 and over | 8 | 2010 | 7061 | 0.060 |
Why?
|
| Humans | 20 | 2021 | 93515 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2008 | 512 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2010 | 1524 | 0.060 |
Why?
|
| Neoplasm Staging | 5 | 2009 | 2017 | 0.060 |
Why?
|
| Surveys and Questionnaires | 3 | 2008 | 2802 | 0.060 |
Why?
|
| Middle Aged | 13 | 2010 | 27573 | 0.060 |
Why?
|
| Male | 14 | 2010 | 44557 | 0.060 |
Why?
|
| Neoplasms | 1 | 2020 | 3169 | 0.060 |
Why?
|
| Arousal | 1 | 2005 | 171 | 0.060 |
Why?
|
| Adult | 10 | 2010 | 27918 | 0.050 |
Why?
|
| Social Environment | 1 | 2005 | 194 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2008 | 603 | 0.050 |
Why?
|
| Follow-Up Studies | 5 | 2009 | 3830 | 0.050 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2008 | 378 | 0.050 |
Why?
|
| Risk | 2 | 2020 | 657 | 0.050 |
Why?
|
| Prostate | 1 | 2007 | 416 | 0.050 |
Why?
|
| Biopsy, Needle | 3 | 2009 | 225 | 0.050 |
Why?
|
| Aged | 10 | 2010 | 20434 | 0.050 |
Why?
|
| Probability | 3 | 2009 | 355 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 1395 | 0.050 |
Why?
|
| Ethanol | 1 | 2005 | 273 | 0.050 |
Why?
|
| Attitude of Health Personnel | 1 | 2008 | 660 | 0.050 |
Why?
|
| Motivation | 1 | 2005 | 310 | 0.050 |
Why?
|
| Comorbidity | 2 | 2021 | 1007 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2009 | 1077 | 0.050 |
Why?
|
| Healthcare Disparities | 1 | 2008 | 486 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2005 | 1729 | 0.040 |
Why?
|
| Organ Size | 3 | 2007 | 362 | 0.040 |
Why?
|
| Prognosis | 3 | 2020 | 3911 | 0.040 |
Why?
|
| Melanoma | 1 | 2005 | 495 | 0.040 |
Why?
|
| Physicians | 1 | 2008 | 682 | 0.040 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 37 | 0.040 |
Why?
|
| United Kingdom | 1 | 2020 | 190 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2008 | 1133 | 0.040 |
Why?
|
| Female | 9 | 2010 | 48702 | 0.040 |
Why?
|
| Triage | 1 | 2020 | 131 | 0.040 |
Why?
|
| Hyperplasia | 2 | 2009 | 147 | 0.040 |
Why?
|
| Mucous Membrane | 2 | 2009 | 82 | 0.040 |
Why?
|
| Prospective Studies | 4 | 2008 | 4560 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2010 | 457 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2020 | 375 | 0.030 |
Why?
|
| Cohort Studies | 3 | 2009 | 3054 | 0.030 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2009 | 283 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2020 | 404 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2008 | 2365 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2010 | 1723 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2008 | 985 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2009 | 1799 | 0.030 |
Why?
|
| Disease Progression | 2 | 2012 | 1531 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2005 | 2303 | 0.030 |
Why?
|
| Prevalence | 2 | 2009 | 1321 | 0.030 |
Why?
|
| Time Factors | 3 | 2009 | 5410 | 0.030 |
Why?
|
| Biopsy | 2 | 2007 | 1175 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2007 | 1713 | 0.020 |
Why?
|
| Microvessels | 1 | 2012 | 68 | 0.020 |
Why?
|
| Retrospective Studies | 3 | 2009 | 10164 | 0.020 |
Why?
|
| Mitoxantrone | 1 | 2010 | 65 | 0.020 |
Why?
|
| Cytarabine | 1 | 2010 | 216 | 0.020 |
Why?
|
| Neutropenia | 1 | 2010 | 209 | 0.020 |
Why?
|
| Alemtuzumab | 1 | 2009 | 90 | 0.020 |
Why?
|
| CD3 Complex | 1 | 2009 | 135 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2010 | 272 | 0.020 |
Why?
|
| Quality of Life | 2 | 2008 | 1780 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2010 | 189 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 217 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 302 | 0.020 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2008 | 86 | 0.020 |
Why?
|
| Tacrolimus | 1 | 2009 | 372 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2008 | 140 | 0.020 |
Why?
|
| Taxoids | 1 | 2008 | 126 | 0.020 |
Why?
|
| Etoposide | 1 | 2008 | 204 | 0.020 |
Why?
|
| Metaplasia | 1 | 2007 | 39 | 0.020 |
Why?
|
| Illinois | 1 | 2009 | 520 | 0.020 |
Why?
|
| Young Adult | 2 | 2010 | 6930 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2008 | 361 | 0.020 |
Why?
|
| Awareness | 1 | 2008 | 89 | 0.020 |
Why?
|
| Leukemia | 1 | 2009 | 301 | 0.020 |
Why?
|
| Graft vs Host Disease | 1 | 2009 | 365 | 0.020 |
Why?
|
| Carboplatin | 1 | 2008 | 322 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2009 | 1014 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2009 | 394 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2010 | 1587 | 0.020 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2007 | 160 | 0.020 |
Why?
|
| Remission Induction | 1 | 2008 | 738 | 0.020 |
Why?
|
| Cisplatin | 1 | 2008 | 568 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2008 | 504 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2007 | 579 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2007 | 356 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2010 | 665 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2008 | 889 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2010 | 697 | 0.010 |
Why?
|
| ErbB Receptors | 1 | 2008 | 506 | 0.010 |
Why?
|
| Intraoperative Complications | 1 | 2007 | 195 | 0.010 |
Why?
|
| Crosses, Genetic | 1 | 2005 | 165 | 0.010 |
Why?
|
| Prostate-Specific Antigen | 1 | 2007 | 337 | 0.010 |
Why?
|
| Carbon Monoxide | 1 | 2005 | 98 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 2005 | 224 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2005 | 239 | 0.010 |
Why?
|
| Random Allocation | 1 | 2005 | 307 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2010 | 1338 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2005 | 259 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2005 | 208 | 0.010 |
Why?
|
| Survival Rate | 1 | 2008 | 1948 | 0.010 |
Why?
|
| Body Weight | 1 | 2005 | 449 | 0.010 |
Why?
|
| Mice | 2 | 2010 | 12269 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 829 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2009 | 1001 | 0.010 |
Why?
|
| Age Factors | 1 | 2008 | 1906 | 0.010 |
Why?
|
| Logistic Models | 1 | 2007 | 1243 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2008 | 1847 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 1917 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2005 | 1061 | 0.010 |
Why?
|
| Liver | 1 | 2005 | 1210 | 0.010 |
Why?
|
| Kidney | 1 | 2005 | 1111 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2007 | 1660 | 0.010 |
Why?
|
| Lung | 1 | 2005 | 1366 | 0.010 |
Why?
|
| Animals | 2 | 2010 | 28155 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2005 | 3435 | 0.010 |
Why?
|
| Risk Factors | 1 | 2007 | 5899 | 0.010 |
Why?
|
| Adolescent | 1 | 2009 | 9606 | 0.010 |
Why?
|